Clinical trial · Observational
Malignancies in Transplanted Patients
Follow-up of Malignancies in Transplanted Patients
NCT02241564CI-TRIAL-00030054MALTXcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection | Other | — | UNRESOLVED |
| Switch from calcineurin inhibitor to an mTOR inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Malignancy post transplantation
- interventionNames
- Other: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection
- Drug: Switch from calcineurin inhibitor to an mTOR inhibitor
Primary outcomes (1)
- measure
- Patient survival
- timeFrame
- 12 months, 2 years, 3 years
- description
- After inclusion
Secondary outcomes (5)
- measure
- Graft survival
- timeFrame
- 12 months, 2 years, 3 years
- description
- After inclusion
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients willing and capable of giving written informed consent of participation in the project * Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma) Exclusion Criteria: * Patients with a primary liver cancer as cause of the transplantation
References
Publications (2)
- BACKGROUNDHellstrom V, Lorant T, Dohler B, Tufveson G, Enblad G. High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Transplantation. 2017 Jun;101(6):1295-1302. doi: 10.1097/TP.0000000000001225. PMID 27163539
- DERIVEDHellstrom VC, Enstrom Y, von Zur-Muhlen B, Hagberg H, Laurell A, Nyberg F, Backman L, Opelz G, Dohler B, Holmberg L, Tufveson G, Enblad G, Lorant T. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study. Acta Oncol. 2016 Jun;55(6):774-81. doi: 10.3109/0284186X.2015.1130855. Epub 2016 Jan 29. PMID 26824275